Codagenix Inc. today announced the completion of a $25 million Series B extension financing, with participation from a new investor, the Serum Institute of India Pvt. Ltd., along with existing investors Euclidean Capital and Adjuvant Capital.
| Funding supports continued clinical studies for pediatric RSV and universal influenza vaccine candidates as well as expanded indications for oncology vertical FARMINGDALE, N.Y. and CAMBRIDGE, Mass., Feb. 15, 2023 /PRNewswire/ -- Codagenix, Inc., a clinical-stage synthetic biology company with a rational virus design platform for live-attenuated viral vaccines and immuno-oncology therapeutics, today announced the completion of a $25 million Series B extension financing, with participation from a new investor, the Serum Institute of India Pvt. Ltd., along with existing investors Euclidean Capital and Adjuvant Capital.
Proceeds from the financing will support the clinical development of CodaVax™-RSV, an intranasal, live-attenuated vaccine candidate, for the prevention of respiratory syncytial virus (RSV) disease. Codagenix is set to begin dosing in a Phase 1 trial in healthy infants and toddlers in early 2023. The primary disease burden and hospitalizations during the previous 2022 RSV season were in the pediatric population, not older adults, and Codagenix has been granted Fast-Track designation by the U.S. Food and Drug Administration (FDA) to help solve this urgent unmet need. CodaVax-RSV is highly differentiated as it does not utilize a backbone virus, nor does it have genetic deletions to support induction of an immune response to the complete antigenic composition of the virus in children. The funding will also support additional cohorts in an ongoing Phase 1 study for CodaVax™-H1N1, a universal, live-attenuated influenza vaccine in 1H23 and expansion of the company’s oncology program to new indications, utilizing its platform for rational, indication-focused virotherapeutics. The advanced development of the company’s intranasal COVID-19 vaccine candidate CoviLiv™ is currently being evaluated in the Solidarity Trial Vaccines (STV) which is supported by the World Health Organization (WHO) and the Serum Institute of India. STV is a placebo-controlled, Phase 3 safety and efficacy study with the primary endpoint of prevention of confirmed COVID-19 clinical disease. With completion of the STV study, Codagenix may be able to demonstrate primary efficacy of their COVID-19 vaccine platform potentially enabling CoviLiv to be developed as a future seasonal-COVID-19 vaccine. “It is exciting to now have the Serum Institute of India as a direct investor, building upon our successful partnership in the development of CoviLiv and, of course, we thank Euclidean Capital and Adjuvant Capital for their continued support and belief in our differentiated platform,” said J. Robert Coleman, Ph.D., M.B.A., Co-Founder and Chief Executive Officer of Codagenix. “This financing positions us well to advance our deep clinical pipeline, including live-attenuated vaccine candidates in RSV, that has the potential to meet a critical unmet need as well as further demonstrate our platform’s ability to design custom virotherapeutics for solid-tumors.” About Codagenix, Inc. Media Contact Investor Relations Contact
SOURCE Codagenix, Inc. |
View original content to download multimedia:
